BIIB : Analysis & Opinions

  1. Will Biogen (BIIB) Surpass Q4 Earnings Expectations? - Analyst ...

    January 27, 2015
    Investor focus will remain on Biogen's (BIIB) oral MS treatment, Tecfidera's, performance.
  2. Biotech Stock Roundup: EU Approvals for AbbVie & Celgene Drugs, ...

    January 21, 2015
    The hepatitis C virus (HCV) pricing battle is heating up with Gilead (GILD) signing on with quite a few PBMs and health care ...
  3. Stock Market News for January 21, 2015 - Market News

    January 21, 2015
    Benchmarks ended Tuesday’s choppy trading session in the green led by gains from technology shares
  4. Isis Pharmaceuticals Earns Milestone Payment from Biogen - Analyst ...

    January 15, 2015
    Isis Pharmaceuticals (ISIS) earned a milestone payment of $7 million from partner Biogen for the advancement of the ongoing ...
  5. The Biggest Biotech Companies

    January 15, 2015
    These biotech firms want to revolutionize medicine. If successful, they may see high profits, but investing in these companies ...
  6. Adapt The 50-Day EMA To Enhance Your Trading

    January 14, 2015
    The 50-day EMA has numerous applications in price prediction, position choice & strategy building
  7. Biogen to Acquire Convergence, Expand Pain Pipeline - Analyst ...

    January 13, 2015
    Biogen's (BIIB) upcoming acquisition of Convergence should strengthen its pain pipeline.
  8. Seattle Genetics, Bristol-Myers to Study Adcetris-Opdivo - Analyst ...

    January 13, 2015
    Seattle Genetics, Inc. (SGEN) and partner Bristol-Myers Squibb Company inked a deal to develop an investigational combination ...
  9. Biogen Reveals Positive Data from Acute Optic Neuritis Study ...

    January 9, 2015
    Biogen Idec (BIIB) announced positive top-line results from a phase II study on anti-LINGO-1 for the treatment of patients ...
  10. Isis Pharmaceuticals Improves 2014 Outlook, Shares Up - Analyst ...

    January 9, 2015
    Isis Pharmaceuticals (ISIS) gained around 4.9% after the company updates its 2014 outlook.
  11. Biotech Stock Roundup: Kite Flies High on Amgen Deal, Isis Soars ...

    January 7, 2015
    Collaborations and agreements continued to make headlines in the biotech sector with companies like Gilead (GILD), Amgen ...
  12. Isis Pharmaceuticals Up on Collaboration with J&J - Analyst ...

    January 6, 2015
    Isis Pharmaceuticals (ISIS) inked a global collaboration with Johnson & Johnson's (JNJ) Janssen Biotech, Inc for the ...
  13. Vertex Pharmaceuticals' Kalydeco Label Expanded in the U.S. - ...

    December 30, 2014
    Vertex Pharmaceuticals Incorporated (VRTX) received good news when the FDA approved its supplemental new drug application ...
  14. Ignyta's Lead Oncology Candidate Gets Orphan Drug Status - Analyst ...

    December 30, 2014
    Ignyta, Inc.'s (RXDX) lead candidate, entrectinib (RXDX-101), received orphan drug status and rare pediatric disease designation ...
  15. Stock Market News for December 26, 2014 - Market News

    December 26, 2014
    Markets ended modestly higher on Wednesday’s abbreviated trading session banking on initial claims dropping to a seven-week ...
  16. After Gilead Sciences, Is it Time to Sell Biotech Stocks? - Analyst ...

    December 26, 2014
    Gilead Sciences Inc. has plunged approximately 15.8% after pharmacy benefit manager Express Scripts entered into an agreement ...
  17. Vanda Gains Fanapt Rights from Novartis for the U.S. Region ...

    December 24, 2014
    Vanda Pharmaceuticals Inc. (VNDA) recently announced that it has reached a settlement agreement with Novartis AG (Novartis) ...
  18. Stock Market News for December 24, 2014 - Market News

    December 24, 2014
    Benchmarks mostly settled in the green on Tuesday banking on better-than-expected revision to third quarter GDP numbers
  19. Biotech Stock Roundup: AbbVie's HCV Treatment Approved, ImmunoGen ...

    December 24, 2014
    Will Express Scripts' announcement regarding AbbVie's (ABBV) Viekira Pak lead to a pricing war in the hepatitis C virus (HCV) ...
  20. Orexigen's Obesity Drug Mysimba Gets CHMP Nod - Analyst Blog

    December 22, 2014
    The CHMP gave a positive opinion on the approval of Orexigen's (OREX) weight loss drug, Mysimba.
  21. Genomic Health (GHDX) Shines on Prospective Cancer Tests - Analyst ...

    December 22, 2014
    Genomic Health (GHDX) strongly believes that its Oncotype DX prostate cancer test will strengthen its advanced next generation ...
  22. Roche to Acquire Austrian Biotechnology Company Dutalys - Analyst ...

    December 22, 2014
    Roche (RHHBY) recently announced it has agreed to acquire a privately-held Austrian biotechnology company named Dutalys GmbH.
  23. Celgene Gets Positive CHMP Recommendation for Revlimid - Analyst ...

    December 22, 2014
    Celgene Corporation announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has rendered ...
  24. Novo Nordisk's Tresiba Favored by CHMP for Expanded Use - Analyst ...

    December 22, 2014
    Novo Nordisk (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended Tresiba for expanded ...
  25. Eli Lilly-Adocia Strike Deal to Develop Ultra-Rapid Insulin - ...

    December 22, 2014
    Eli Lilly and Company (LLY) and Adocia entered into a licensing agreement to develop an ultra-rapid insulin, BioChaperone ...
  26. Agenus Jumps on Positive Data from Shingles Candidate - Analyst ...

    December 19, 2014
    Shares of Agenus Inc. (AGEN) jumped after its partner GlaxoSmithKline (GSK) announced encouraging results on HZ/su.
  27. Integra Lifesciences Up on Launch of Bilayer Skin Product - ...

    December 19, 2014
    This latest single-use skin product of Integra (IART) is at present the only pre-meshed bilayer matrix that has been approved ...
  28. Seattle Genetics Initiates Phase Ib Study on Leukemia Drug - ...

    December 19, 2014
    Seattle Genetics, Inc. (SGEN) has initiated a phase Ib study on SGN-CD33A for newly diagnosed acute myeloid leukemia.
  29. Bruker Unveils bioAFM System for High Resolution Imaging - Analyst ...

    December 18, 2014
    Bruker's (BRKR) BioScope Resolve provides real-time correlation of atomic force microscopy and optical microscopy data sets
  30. Alkermes Starts Phase I Study on Schizophrenia Candidate - Analyst ...

    December 16, 2014
    Alkermes (ALKS) announced the commencement of a phase I extended dosing study on aripiprazole lauroxil for the treatment ...
  31. Acorda's Ampyra in Phase III for Post-Stroke Walking Deficit ...

    December 16, 2014
    Acorda (ACOR) has commenced a phase III study on Ampyra for the treatment of post-stroke walking deficits.
  32. Is Illumina (ILMN) Worth Adding to Your Portfolio? - Analyst ...

    December 16, 2014
    On Dec 10, 2014, we issued an updated research report on Illumina Inc. (ILMN).
  33. Genomic Health's Breast Cancer Test Yields Positive Results - ...

    December 16, 2014
    Oncotype DX breast cancer test ??? as Genomic Health's (GHDX) first product ??? has been an important contributor to U.S. ...
  34. Stock Market News for December 16, 2014 - Market News

    December 16, 2014
    Markets finished a choppy session in the negative territory on Monday as yet another slide in oil prices dented investor ...
  35. Alexion's Soliris Receives Orphan Drug Status in Japan - Analyst ...

    December 15, 2014
    Alexion (ALXN) announced that Soliris has received orphan drug designation in Japan for the treatment of myasthenia gravis.
  36. Jazz Pharmaceuticals Starts Defibrotide Rolling NDA Filing - ...

    December 15, 2014
    Jazz Pharmaceuticals (JAZZ) has started the rolling submission of a NDA for defibrotide.
  37. Biotechnology Stocks To Keep on the Radar

    April 23, 2014
    Health care is showing a resurgance, lead by biotechnology. Here are the opportunites to watch.
  38. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  39. Bull of the Day: Quintiles (Q) - Bull of the Day

    March 5, 2014
    Bull of the Day: Quintiles (Q) - Bull of the Day
  40. Four Breakout Stocks To Watch

    February 19, 2014
    These biotechnology and pharmaceutical stocks continue to put in new highs, but indicators are diverging.
  41. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  42. Focusing on Healthcare and Financials this Week

    November 25, 2013
    Health Care and Financials dramatically outpaced the other sectors last week as the S&P 500 created a new high . With only ...
  43. A Strong Prognosis For Healthcare Stocks

    November 19, 2013
    Despite the healthcare sectors recent torrid run, there’s still plenty to like about stocks in the industry. Aside from tailwinds ...
  44. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    November 12, 2013
    Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals ...
  45. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    September 14, 2013
    Declining short interest in Alexion Pharmaceuticals (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical ...
  46. Can Sanofi Investors Just Blame It On Rio?

    August 6, 2013
    Can Sanofi Investors Just Blame It On Rio? By Stephen D. Simpson, CFA Sanofi (NYSE: SNY) was supposed to be a relatively ...
  47. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  48. Glaxo Gets Offer for Thrombosis Drugs - Analyst Blog

    June 19, 2013
    GlaxoSmithKline announced that Aspen Pharmacare Holdings Limited has offered to buy Glaxo's thrombosis brands
  49. Perrigo in Expansion Mode - Analyst Blog

    June 18, 2013
    Perrigo has purchased Fera's eye-care portfolio.
  50. Elan Shareholders Bring Management To Heel

    June 17, 2013
    The rejection of Elan management's proposed transactions ought to accelerate the sale of the company.
  51. Bull of the Day: Biogen (BIIB) - Bull of the Day

    June 14, 2013
    Bull of the Day: Biogen (BIIB) - Bull of the Day
  52. After A Good Run, Novartis Looks Fairly Valued

    June 12, 2013
    Novartis is a well-balanced, high-quality pharma with growth credentials, but also a fair valuation today.
  53. 3 Impressive Biotech ETFs Crushing the Market - ETF News And ...

    June 11, 2013
    Rotate into the outperforming biotech sector with these three ETFs.
  54. 10 Picks from 2 Strong Sectors

    June 10, 2013
    As we enter the bumpy summer months, large-cap US domestic stocks and health-care names are on Louis Navellier's list, and ...
  55. Amgen Chased By The Bubble

    May 8, 2013
    Amgen really needs the pipeline to come through to support this valuation.
  56. Strategy for Trading High Flying Healthcare Stocks

    April 17, 2013
    Over the past week, month and three months, the healthcare sector has been the top performer.
  57. ELN/BIIB Seek Label Expansion - Analyst Blog

    January 17, 2013
    Biogen Idec Inc. (BIIB) and partner Elan Corporation (ELN) recently submitted applications to the US Food and Drug Administration ...
  58. PDLI Guides Q4 Royalty Rev to $86M - Analyst Blog

    December 7, 2012
    PDL BioPharma Inc. (PDLI) recently announced that it expects to generate fourth quarter 2012 royalty revenues of $86 million, ...
  59. Teva Likely To Tread Water Ahead Of New Strategy

    November 5, 2012
    Teva has restructuring and growth opportunities, but the risk is still elevated.
  60. Alnylam-ISIS Venture Prices IPO - Analyst Blog

    October 5, 2012
    Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals (ALNY) and Isis Pharmaceuticals, Inc. (ISIS), recently announced ...
  61. Biogen Idec - Momentum

    September 24, 2012
    Positive earnings estimate revisions, a strong second quarter and an upbeat guidance for 2012 helped Biogen Idec, Inc. (BIIB) ...
  62. Isis Pharma Stays Neutral - Analyst Blog

    July 11, 2012
    We recently reiterated our Neutral recommendation on Isis Pharmaceuticals (ISIS), which carries a Zacks #3 Rank (short-term ...
  63. Rising Trend Channel Breakouts - Acceleration Or Top?

    July 4, 2012
    These stocks have been within rising trend channels, but recently have broken the trend channel to the upside. Such a breakout ...
  64. Biotech ETFs Hitting Highs

    May 17, 2012
    Biotech ETFs are hitting all-time highs and XBI looks like the best of the group. Because the ETF is already up 25% in 2 ...
  65. Best S&P 500 Stocks Of 2011

    January 5, 2012
    The best performing stocks in the S & P 500 in 2011 were concentrated in the energy and health care sectors.
  66. Can The Big Gains Continue Into 2012?

    January 3, 2012
    Learn the opportunities and risks that await some top performers in 2012.
  67. Sanofi's Investment Prospects

    December 21, 2011
    Sanofi has emerged as an unheralded value in pharmaceuticals.
  68. 2011's Highest Performing S&P500 stocks

    December 15, 2011
    Check out 2011's highest-performing S&P 500 stocks.
  69. How to Use Technicals to Trade ETFs

    November 7, 2011
    A couple of health-care growth names are performing well after earnings, says Ken Shreve, who also shares his methodology ...
  70. Biogen Idec Has Built A Valuable Franchise

    November 1, 2011
    Biogen Idec is a go-to name in MS that carries a lot of value. A credible buy for those with longer horizons.
  71. Abbott Labs Joins The Separation Movement

    October 24, 2011
    Abbott is joining the separation movement that is sweeping across corporate America. The company plans to break into a medical ...
  72. Betting On Healthcare's Growth Engine

    August 17, 2011
    In the wake of big pharma's patent cliff and slowing R&D spending, the biotech sector is looking good for investors.
  73. 6 Overbought Stocks To Watch

    April 25, 2011
    Let's take a look at a few stocks that have recently entered overbought territory because these could be candidates for a ...
  74. Human Genome Takes A Big Step Forward

    November 17, 2010
    HGSI's prospects get a big boost from a panel approval.
  75. 4 Companies That Should Have Sold Out

    September 9, 2010
    When company management gets unreasonably stubborn and refuses a merger or buyout, shareholders often pay the price.
  76. Biotech Stocks Ready Ready To Break Out

    September 7, 2010
    Biotech Stocks Ready Ready To Break Out
  77. Another Setback For Roche Is Bad News For ImmunoGen

    August 27, 2010
    Roche suffers another setback to its key cancer franchise, while ImmunoGen faces a major delay in royalty payments.
  78. Big Pharma's Big Problem

    August 16, 2010
    Big Pharma's best patents are expiring, but it may be able to reinvent itself through acquisitions.
  79. Biotech Bargains

    June 17, 2010
    High-growth biotech stocks are now priced like value plays.
  80. 3 Great But Misunderstood Stocks

    May 4, 2010
    Is a lack of understanding of these 3 stocks causing some investors to miss the boat?
  81. Cash Rich, No Debt Stocks

    February 8, 2010
    Anytime you can find a company with lots of cash and little or no debt, it's worth a closer look.
  82. Short The Weak Stocks

    May 11, 2009
    Retailers often flock to short high-profile stocks that have gained in price during a downturn, but they may have better ...
  83. Is Now The Time To Buy Pharmaceuticals?

    May 5, 2009
    Despite the recession, the pharmaceutical sector continues to show strong year-over-year earnings results and demand worldwide.
  84. Money Flowing Into Biotech Stocks

    January 12, 2009
    Institutions have their eyes on biotech stocks. Does this sector have your attention?
Trading Center